

Efficacy of Aflapin® in the treatment of osteoarthritis of knee

Submission date 05/09/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 06/04/2010	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 14/02/2012	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Amar Anand Vishal

Contact details
Department of Orthopaedics
ASR Academy of Medical Sciences
Eluru
India
534 002

Additional identifiers

Protocol serial number
09-002/Aflapin®/OA

Study information

Scientific Title
Efficacy of Aflapin® in the treatment of osteoarthritis of knee: a randomised, double-blind placebo controlled clinical study

Study objectives

Aflapin® is an improved novel composition of *Boswellia serrata* extract standardised to 30% 3-O-acetyl-11-keto-beta-boswellic acid (BE-30). Pre-clinical studies demonstrate that Aflapin® is up to 25% more bioavailable than BE-30. Therefore, we hypothesise that Aflapin® would provide faster relief from clinical symptoms of osteoarthritis (OA).

Results of a related study with BE-30 against osteoarthritis can be found at: <http://www.ncbi.nlm.nih.gov/pubmed/18667054> (this trial is registered with ISRCTN05212803).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Institutional Review Board (IRB) of Alluri Sitarama Raju Academy of Medical Sciences (ASRAM) approved on the 1st August 2009.

Study design

Randomised placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Osteoarthritis

Interventions

60 subjects randomised into 2 groups (n = 30):

1. Aflapin® (oral) 50 mg twice daily (bid)
2. Placebo

Ibuprofen will be used as a rescue medication for both groups. The study duration is 30 days and evaluations will be at baseline, 5, 15 and 30 days.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Aflapin®

Primary outcome(s)

1. Pain, assessed by VAS
2. LFI
3. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)-pain, WOMAC-stiffness and WOMAC-physical ability

Measured at baseline, 5, 15 and 30 days of the study.

Key secondary outcome(s)

1. Tumor necrosis factor alpha (TNF α)
2. C-reactive protein (CRP)
3. Matrix metalloproteinase-3 (MMP-3)

Measured at baseline, 5, 15 and 30 days of the study.

Completion date

01/11/2009

Eligibility

Key inclusion criteria

1. Participants must understand risks and benefits of the protocol and able to give informed consent
2. Male and female subjects of 40 - 80 years of age
3. Females of child bearing potential must agree to use an approved form of birth control and have a negative pregnancy test result
4. Unilateral or bilateral OA of the knee for more than 3 months
5. Visual Analogue Scale (VAS) score during the most painful knee movement between 40 - 70 mm after 7 day withdrawal of usual medication
6. Lequesne's Functional Index (LFI) score greater than 7 points after 7 days of withdrawal of usual medication
7. Ability to walk
8. Availability for the duration of the entire study period

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. History of underlying inflammatory arthropathy or severe rheumatoid arthritis (RA)
2. Hyperuricemia (greater than 440 $\mu\text{mol/L}$) and/or past history of gout
3. Recent injury in the area affected by OA of the knee (past 4 months) and expectation of surgery in the next 4 months
4. Intra-articular corticosteroid injections within the last 3 months
5. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), abnormal liver or kidney function tests, history of peptic ulceration and upper gastrointestinal (GI) haemorrhage, congestive heart failure, hypertension, hyperkalemia
6. Major abnormal findings on complete blood count, history of coagulopathies, haematological or neurological disorders
7. High alcohol intake (greater than 2 standard drinks per day)

8. Pregnant, breastfeeding or planning to become pregnant during the study
9. Use of concomitant prohibited medication other than ibuprofen
10. Obesity: body mass index (BMI) more than 30 kg/m²

Date of first enrolment

01/09/2009

Date of final enrolment

01/11/2009

Locations

Countries of recruitment

India

Study participating centre

Department of Orthopaedics

Eluru

India

534 002

Sponsor information

Organisation

Laila Impex R&D Center (India)

ROR

<https://ror.org/05q6g7072>

Funder(s)

Funder type

Industry

Funder Name

Laila Impex R&D Center (India)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2011		Yes	No